

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 87194

Title: Cohort study to assess geographical variation in cholangiocarcinoma treatment in

England

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04420302 Position: Peer Reviewer Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Brunei Darussalam

Author's Country/Territory: United Kingdom

Manuscript submission date: 2023-08-07

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-08-08 01:40

Reviewer performed review: 2023-08-18 12:50

Review time: 10 Days and 11 Hours

| Scientific quality Good | |
|---|------|
| [] Grade D: Fair [] Grade E: Do not publish | |
| Novelty of this manuscript [] Grade A: Excellent [Y] Grade B: Good [] Grade C: [] Grade D: No novelty | Fair |
| Creativity or innovation of [] Grade A: Excellent [] Grade B: Good [Y] Grade C: | Fair |
| this manuscript [] Grade D: No creativity or innovation | |



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

| Scientific significance of the conclusion in this manuscript | [] Grade A: Excellent [] Grade B: Good [Y] Grade C: Fair [] Grade D: No scientific significance |
|--|--|
| Language quality | [Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection |
| Conclusion | [] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection |
| Re-review | [Y] Yes [] No |
| Peer-reviewer statements | Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No |

SPECIFIC COMMENTS TO AUTHORS

This manuscript by Jose et al is a retrospective cohort study to "assess geographical variation in cholangiocarcinoma treatment in England". Due to cholangiocarcinoma (CCA) being a rare disease with heterogenous subtypes that is tough to diagnose and manage, the authors aimed to investigate how treatments differ in various locations within England. Three datasets were utilised in this study, namely, The National Cancer Registration Dataset (NCRD), Hospital Episode Statistics and the Systemic Anti-Cancer Therapy Dataset. Patients diagnosed within the four-year period between 2014 and 2017 were studied. The three end-points of interests were 1. Potentially curative surgery for all patients 2. Systemic therapy and 3. Stent insertion. The authors concluded that "Substantial regional variation in treatment could be due to differences in case-mix, clinical practice or access to specialist expertise".



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 87194

Title: Cohort study to assess geographical variation in cholangiocarcinoma treatment in

England

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05266421 Position: Peer Reviewer Academic degree: PhD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: United Kingdom

Manuscript submission date: 2023-08-07

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-08-31 07:17

Reviewer performed review: 2023-08-31 08:21

Review time: 1 Hour

| | [] Grade A: Excellent [] Grade B: Very good [Y] Grade C: |
|-----------------------------|---|
| Scientific quality | Good |
| | [] Grade D: Fair [] Grade E: Do not publish |
| Novelty of this manuscript | [] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty |
| Creativity or innovation of | [] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair |
| this manuscript | [] Grade D: No creativity or innovation |
| | |



Baishideng

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

| Scientific significance of the conclusion in this manuscript | [] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance |
|--|---|
| Language quality | [] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection |
| Conclusion | [] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection |
| Re-review | [Y] Yes [] No |
| Peer-reviewer statements | Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No |

SPECIFIC COMMENTS TO AUTHORS

The topic is very interesting and the statistical method is quite rational. However, I have some questions as follows: Major: 1) as a clinician, I pay more attention to the survival data. The authors should first make clear whether the treatment options could influence the survival of patients, considering that they enrolled patients between 2014 and 2017, which means sufficient follow-up 2) the results in the "Abstract" are too simple to reach the conclusionn in the "Abstact" and the "core tip", and more detailes should be added; 3) the authors pay attention to the assocaition between treatment options and patients and tumor, but another factor, local medician condiction, is not underpined. 4) the percentage of patients receiving non specific treatment in the European Reference Network for the Study of Cholangiocarcinoma was 20%, but it was 50%. the authors should explain why? 5) in the European Reference Network for the Study of Cholangiocarcinoma, around 20% did not receive any specific cancer therapy, but best supportive care only. To the best of knowledge, the beat support care is also an option for patients; and therefore, i wonder if 50% of CCA patients in England did not receive any treatment including the best suport care Minor: 1) in the "Introduction", the author



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

stated that "CCA comprise the second most common form of primary liver cancer worldwide, after hepatocellular carcinoma" in Line 15-16, but I think it is not appropriate. eCCA could not be cateroried into primary liver cancer. 2) in the "Introduction", the authors undeliend the differences amongst the three sub-types, but I think it should be weakened and more common characteristics might be appropriate here